非酒精性脂肪性肝炎联合治疗:依据、机遇与挑战
非酒精性脂肪性肝炎(NASH)正成为肝硬化的主要病因,相关并发症负担预计将大幅增加。目前多种不同作用机制的分子正在研发中,但迄今报道的疗效有限。鉴于NASH病理生理的复杂性,需要多个靶点和通路的参与来改善药物干预效果,这为联合治疗提供了依据。本文基于当前治疗格局综述了联合治疗NASH的依据及其优势与局限。
要点
- NASH正成为肝硬化主要病因,相关并发症负担预计大幅增加。
- 多种不同机制药物在研,但迄今报道疗效有限。
- NASH病理生理复杂,需多靶点通路参与,支持联合治疗。
核心结论
- NASH病理生理复杂,需多靶点通路参与以改善药物干预效果,为联合治疗提供依据。
研究设计与样本
- 综述文章,基于当前NASH治疗格局讨论联合治疗的依据、优势与局限。
主要发现
- 多种不同作用机制的分子正在研发用于治疗NASH,但迄今报道的疗效有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.
引用
- Dufour JF, Caussy C, Loomba R, et al. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020. PMID: 32381514. doi:10.1136/gutjnl-2019-319104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。